Compare Iron Mountain Inc (IRM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Iron Mountain Inc trades at $114.47 (market cap $34.46B), while Vertex Pharmaceuticals Incorporated trades at $509.61 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.7× Iron Mountain Inc's market cap, and Iron Mountain Inc pays a 2.99% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IRM | VRTX | |
|---|---|---|
Market Cap | $34.46B | $127.55B |
Volume | 1,379,608 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $557.96 |
52-Week Low | $78.86 | $407.37 |
Typical Hold Time | 80 Days | 120 Days |
Enterprise Value | $53.87B | $121.68B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong institutional interest. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent news highlights expansion in data centers and digital partnerships, including a 300MW pipeline and AI collaborations.
The outlook is supported by analyst consensus with a $142.75 price target (66.7% buy ratings), but high debt levels and elevated P/E of 82.09 pose risks. Earnings growth from digital initiatives is the key catalyst, while leverage and margin pressure require monitoring for sustained shareholder value.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
